37646 - Muscular Dystrophy: Drugs (Answered)

Mr David Anderson
To ask the Secretary of State for Health, how many meetings NHS England has had with PTC Therapeutics to discuss an agreement on price for Translarna to treat Duchenne muscular dystrophy since 15 April 2016.

George Freeman

37645 - Muscular Dystrophy: Drugs (Answered)

Mr David Anderson
To ask the Secretary of State for Health, what steps he is taking to ensure that NHS England implements the NICE recommendation for NHS funding for Translarna as a treatment for Duchenne muscular dystrophy.

George Freeman

The National Institute for Health and Care Excellence (NICE) is currently evaluating Translarna (ataluren) for the treatment of Duchenne muscular dystrophy through its highly specialised technology programme. The expected publication date for NICE’s final guidance is July 2016.

37421 - Drugs (Answered)

Andrew Gwynne
To ask the Secretary of State for Health, what legal costs (a) his Department and (b) NHS England have incurred to date in relation to decisions on access to (i) narcolepsy drugs, (ii) hepatitis C drugs and (iii) pre-exposure prophylaxis for HIV.

George Freeman

The Department’s legal costs are met from individual teams’ existing legal budgets and cannot be broken down further. NHS England also advises that it is not able to provide this information as these are live issues incurring ongoing legal costs.

37690 - Muscular Dystrophy: Drugs (Answered)

Greg Mulholland
To ask the Secretary of State for Health, following the announcement on Twitter by the Parliamentary Under-Secretary of State for Life Sciences on 15 April 2016 that a Managed Access Agreement had been reached for the Translarna drug, for what reasons NICE granted a further eight weeks on 4 May 2016 for discussions to take place.

George Freeman

37680 - Medical Treatments (Answered)

Greg Mulholland
To ask the Secretary of State for Health, whether purdah arrangements for the EU referendum apply to policy statements to be published by NHS England on the commissioning of treatments.

George Freeman

Whilst the pre-election guidance for the European Union referendum has yet to be published, it is not anticipated that it would prevent the routine publication of clinical commissioning policy statements which are a ‘business as usual’ function of NHS England.

37420 - Cancer: Drugs (Answered)

Andrew Gwynne
To ask the Secretary of State for Health, how much was spent by the Cancer Drugs Fund in 2015-16; and how much that fund is estimated to spend in 2016-17.

George Freeman

NHS England has advised that it expects to publish information on Cancer Drugs Fund (CDF) expenditure for 2015-16 in Board Papers for NHS England’s Board meeting on 26 May 2016.

37306 - Minoxidil (Answered)

Jim Shannon
To ask the Secretary of State for Health, whether the NHS plans to make minoxidil available to women who have lost their hair.

George Freeman

Minoxidil (Regaine) for the treatment of alopecia is available to purchase ‘over the counter’, without prescription.

Regaine cannot be prescribed in primary care as it is listed in Schedule 1 to the National Health Service (General Medical Service Contracts) (Prescription of Drugs etc.) Regulations 2004 (the ‘blacklist’).

37056 - Medical Records: Disclosure of Information (Answered)

Julian Knight
To ask the Secretary of State for Health, what obligations private hospitals and NHS foundation trusts have to share the medical records of patients who have used both services (a) in general and (b) when such trusts have referred patients to private hospitals.

George Freeman

37279 - NHS: Sustainable Development (Answered)

Norman Lamb
To ask the Secretary of State for Health, if he will take steps to ensure that engagement and consultation with key stakeholders, communities and local voluntary sector organisations is undertaken within each Sustainability and Transformation plan footprint prior to finalisation of those plans.

George Freeman

37278 - NHS: Sustainable Development (Answered)

Norman Lamb
To ask the Secretary of State for Health, whether he plans to assess the extent to which Sustainability and Transformation plans address (a) mental health provision in a locality and (b) the case for the integration of mental and physical health.

George Freeman

Pages